JD.com, Eli Lilly and Company, Abbott Laboratories, Veeva Systems, and Johnson & Johnson are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Eli Lilly bought a stake in Protomer Technologies ... It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide © 2025 Fortune Media IP Limited. All Rights ...

Overseas, Lilly is spending $1.8 billion to expand the production capacity at two plants in Ireland. Lilly also has a $2.5 billion plant under construction in Alzey, Germany, which is expected to ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

WASHINGTON — Eli Lilly plans to spend $27 billion to build four new drug manufacturing sites in the United States, the company announced Wednesday, at a time when the Trump administration is ...

(Reuters) -Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with ...

A larger dose speeds up the onset but also delays the peak effect of regular human insulin. Examples include Humulin R and Novolin R. This type enters the bloodstream slower but has a longer ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...